Drug Trial Radar · NCT01304485
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma
Last checked: Nov 20, 2026Latest source record: Mar 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Actual
Start
Apr 2011
Primary completion
Jan 2019
Study completion Jan 2019
Sponsor
- Lead sponsor
- Phoenix Molecular ImagingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer to select patients who may benefit from directed therapy
Conditions
- Prostate Cancer
Interventions
Sodium Acetate C11Drug
PET Imaging with Sodium Acetate C11
Primary outcomes
What the sponsor says the trial is designed to measure.
- SUV (Standardized Uptake Value)Time frame: Day1 - Assessed at time of PET imaging - i.e. at the time of primary investigation/PET agent administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Phoenix Molecular Imaging
Phoenix, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.